Abstract Details
|
Giovanni Castelnovo
PRESENTER |
No disclosure on file |
| No disclosure on file | |
| Dimitri Renard, MD (CHU Nimes, Hopital Caremeau) | No disclosure on file |
| Marie De Verdal | No disclosure on file |
| Xavier Ayrignac | Xavier Ayrignac has nothing to disclose. |
| Clarisse Carra-Dalliere | No disclosure on file |
| Pierre Labauge, MD | Dr. Labauge has nothing to disclose. |
| Eric Thouvenot, MD, PhD (CHU De Nimes - Hopital Caremeau) | Dr. Thouvenot has received personal compensation in the range of $0-$499 for serving as a Consultant for Biogen. Dr. Thouvenot has received personal compensation in the range of $0-$499 for serving as a Consultant for Merck. Dr. Thouvenot has received personal compensation in the range of $0-$499 for serving as a Consultant for Teva. Dr. Thouvenot has received personal compensation in the range of $0-$499 for serving as a Consultant for Novartis. Dr. Thouvenot has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Thouvenot has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Thouvenot has received research support from Biogen. The institution of Dr. Thouvenot has received research support from Novartis. The institution of Dr. Thouvenot has received research support from Roche. |